




**Supplementary figure 1. mGcm1 and mGcm2 expression.** (A) Immunolabelling of CNS primary cultures for mGcm1 (grey), microglia (CD45, red) and DAPI (blue), N=3; scale bar 10  $\mu$ m. (B) RNA ISH of brain sections on P14, 2 and 18month-old brain sections from control and cko animals: *Cx3cr1* (red), *mGcm2* (green) and DAPI (blue), N=3; scale bar: 10  $\mu$ m. (C) RNAscope labelling on control and cKO brain sections at 18 months: *Cx3cr1* (red), *mGcm1* (green), DAPI (blue), N=3; scale bar: 10  $\mu$ m. (D) Immunolabelling of resident macrophages from lung and adipose tissues at 24month-old animals: mGcm2 (grey), CD45 (red) and DAPI (blue). Scale bar: 100  $\mu$ m. *Cx3cr1-Cre*<sup>+/-</sup>; *mGcm2*<sup>lox/</sup> (control) and *Cx3cr1-Cre*<sup>+/-</sup>; *mGcm2*<sup>lox/lox</sup> (cKO)




**Supplementary figure 2. Characterisation of cell populations in the cortex of 24month-old animals.** (A) Immunolabelling of astrocytes from control and cKO animals for GFAP (red). (B) Quantification of the GFAP area. (C) Immunolabelling of neurons with the pan neuronal marker NeuN (green) and the cell death marker Caspase3 (red). (D) Quantification for double positive NeuN-Caspase3 cells to calculate the neuronal cell death and (E) the total neuronal number. (F) Immunolabelling for oligodendrocytes with Olig2 and (G) quantification of oligodendrocytes in control and cKO animals. (H,J) Open field test for control and cKO animals at 18 months. The animals were evaluated for the total distance covered (H), the percentage of time spent in the centre (I) and how many times they entered in the centre (J). p-value: \* $<0.05$ , \*\* $<0.01$ , \*\*\* $<0.001$ , and ns for not significant. N=5-13; scale bar: 50  $\mu\text{m}$ . Statistical significance was determined by one-way ANOVA followed 2-tailed, unpaired t-test. *Cx3cr1-Cre*<sup>+/-</sup>; *mGcm2*<sup>fllox/</sup> (control) and *Cx3cr1-Cre*<sup>+/-</sup>; *mGcm2*<sup>fllox/fllox</sup> (cKO)



**Supplementary Figure 3. The density of macrophages containing myelin debris is not altered in LPC demyelinated lesions of *mGcm2* icKO mice.** (A) Oil-Red O staining of macrophages with myelin debris in control and *mGcm2* icKO LPC lesions, at 7 and 14 dpi. (B) Quantification of Oil-Red-O<sup>+</sup> area in LPC lesions from 2 to 21 dpi, in control and *mGcm2* icKO animals. (C) Percentage of Oil-Red-O<sup>+</sup> area in LPC lesions from 2 to 21 dpi in both experimental groups. Note that the clearance of myelin debris by macrophages in demyelinated lesions is not altered in *mGcm2* icKO with respect to control mice. Scale bar: (A), 100 $\mu$ m.



**Supplementary Figure 4. Loss of *mGcm2* function in microglia delays oligodendrocyte differentiation in demyelinated lesions.** (A) Immunolabelling with Olig2 (red) and CC1 (green) in LPC lesions of the spinal cord at 14 dpi, in control and *mGcm2* icKO mice. Nuclei are counterstained with DAPI. (B,C) Graphs indicating the percentage of Olig2/CC1-double positive differentiated oligodendrocytes and Olig2-positive/CC1-negative OPCs in demyelinated lesions from 7 to 21 dpi, in control and *mGcm2* icKO mice. (D) Quantification of the number of total Olig2-positive oligodendroglia in LPC lesions at 7, 14 and 21 dpi, in control and *mGcm2* icKO animals. Two-way ANOVA followed by Tukey's multiple comparison tests were used for statistical analysis. \* $p < 0.05$ , \*\* $p < 0.01$ . Scale bar: (A), 100  $\mu\text{m}$ .



**Supplementary Figure 5. An inducible system tracing *gcm* expression.** (A) Immunolabelling of adult *Drosophila* brain with *gcm* tracing (*gcm>g-trace*=GFP) in green, Repo (white), Elav (white) and DAPI (blue). (B) Immunolabelling of adult *Drosophila* brain with *gcm* tracing (*gcm>g-trace*) in green, Repo (grey), Elav (red) and DAPI (blue), Scale bar: 20  $\mu$ m. (C) Immunolabelling of hemocytes from *gcm>g-trace* strain. The pan-hemocyte marker Hemese (red), *g-trace* (green), DAPI (blue). Animals were raised at 18°C and shifted at 29°C at second instar larval. scale bar: 20  $\mu$ m.

Host	Target	Dilution	Reference
mouse	anti-Arginase1	1/200	sc-271430
rat	anti-CD11b	1/400	MCA-74G
rat	anti-CD45	1/50	MCD-4500
rat	anti-CD68	1/400	MCA-1957
rat	anti-F4/80	1/100	MCA-497
rabbit	anti-Gcm1	1/50	B. Nait-Oumesmar
rabbit	anti-Gcm2	1/200	ab201170
rabbit	anti-Iba1	1/300	1919741
mouse	anti-iNOS	1/100	ab210823
mouse	anti-GFAP	1/100	PCN
mouse	anti-NeuN	1/100	ab279296
rabbit	anti-Casp3	1/200	mAb #9664
mouse	anti-MOG	1/20	clone C18C5, C. Linnington
rabbit	anti-Olig2	1/400	AB9610
mouse	anti-APC	1/100	OP80
mouse	anti-HLA	1/100	CR3/43
mouse	anti-Repo	1/20	8D12 (DSHB)
rat	anti-Elav	1/100	7E8A10 (DSHB)
mouse	anti-Hemese	1/40	I. Ando
mouse	anti-L4	1/50	I. Ando
chicken	anti-GFP	1/500	703095155
donkey	anti-mouse-Cy3	1/500	715-165-151
donkey	anti-rabbit-Cy3	1/500	711-165-152
goat	anti-rat-Cy3	1/500	112-165-167
goat	anti-mouse-Alexa647	1/500	115-605-166
goat	anti-rabbit-Cy5	1/500	111-175-144
goat	anti-rat-Cy5	1/500	112-175-144
donkey	anti-chicken-FITC	1/500	A11039
goat	anti-rat-Alexa568	1/1000	A11077
donkey	anti-rat-Alexa488	1/1000	A21208
donkey	anti-rat-Alexa647	1/1000	AB150155
donkey	anti-rabbit-Alexa568	1/1000	A10042
goat	anti-mouse-Alexa488	1/1000	1070-02
donkey	anti-mouse-Alexa488	1/1000	A21202
goat	anti-mouse-FITC	1/100	A21141

**Supplementary Table 1. Primary and secondary antibodies**

MS cases	Age	Sex	PMD	Disease duration	Disease course	Lesions analyzed			
						Active	Chronic active	Chronic inactive	Shadow plaques
MS94CLA6	42	F	11	6	PP	1			
MS100CLC2	46	M	7	8	SP			1	
MS121CLC5	49	F	24	14	PR	1		1	
MS106L6C8	39	F	18	21	PP		1		
<b>Control</b>									
C26CLA5	79	F	18		Cardiac failure				

**Supplementary Table 2. MS and control cases used to study hGCM2 expression**

	<b>Target</b>	<b>Taqman probes</b>
	Hprt	HPRT TaqMan® Gene Expression Assays (Mm03024075_m1)
	mGcm2	GCM2 TaqMan® Gene Expression Assays (Mm00492312_m1)
M1	iNOS	NOS2 TaqMan® Gene Expression Assays (Mm00440502_m1)
M1	TLR2	TLR2 TaqMan® Gene Expression Assays (Mm00442346_m1)
M2a	Arg-1	ARG1 TaqMan® Gene Expression Assays (Mm00475988_m1)
M2b	Il-4ra	IL-4a TaqMan® Gene Expression Assays (Mm01275139_m1)
M2c	CD163	Cd163 TaqMan® Gene Expression Assays (Mm00474091_m1)

**Supplementary Table 3. Taqman probes used for qRT-PCR analysis of LPC lesions**